In an amicus brief submitted to the United States Court of Appeals for the Federal Circuit, AAM urged the Court to reject an interpretation of the law that would have prevented biosimilar developers from utilizing the Inter Partes Review (IPR) process at the U.S. Patent and Trade Office—a process designed to weed out invalid patents in an efficient manner. The IPR process is a critical tool in the effort to bring lower-cost biosimilar and generic medicines to patients as soon as possible.
